Who is the driving force behind the turnover trend in the pharmaceutical industry?

In two years, more than 15 managers above the director level of an enterprise have been replaced, and the old people of the older enterprise have also been replaced In the past two years, personnel changes in pharmaceutical industry enterprises, including foreign capital, joint ventures and local enterprises, have become more frequent Not only are the executives of Pfizer, MSD, AstraZeneca, Roche and other multinational companies frequently changed, but also the top professional managers of local pharmaceutical companies are at the peak of turnover and new appointment The separation and combination of individuals and enterprises makes the whole pharmaceutical industry present a trend of turnover and personnel turnover Although there will be specific differences in the situation of different enterprises and different people, such as foreign capital, local enterprises, and even joint ventures, there are certain rules on the whole "This is the process of industry elimination and the process of talent competition among enterprises!" According to Nie Zilong, chief headhunting consultant of Beijing Mingde Qualification Management Consulting Co., Ltd., the reasons behind the frequent personnel changes in the pharmaceutical industry can be summarized in two aspects: First, the great changes in current pharmaceutical policies make enterprises face the pressure of transformation, compliance and other aspects, and this pressure is transmitted to the management of enterprises, leading to some active or passive resignation; second, in the new era of the development of China's pharmaceutical industry, competition among enterprises is increasingly reflected in the competition for talents Especially in the new stage of transformation and upgrading, some enterprises also need to match more suitable talents Behind the elimination, it is true that in the past two years, China's pharmaceutical policy has changed dramatically, and the whole industry environment has put more and more pressure on enterprises, which undoubtedly brings pressure to the professional managers of enterprises that they have never experienced before A general manager of one of the top 100 domestic enterprises told e pharmaceutical managers: "domestic traditional enterprises, such as some traditional Chinese medicine preparation enterprises, have a tight living space under the requirements of national policies This requires managers at the marshal level to break through the inherent thinking, whether it is strategic thinking or the use of tactics, must look for a longer term and find a new breakthrough point Being unable to adapt to this change may be the biggest reason for some professional managers to leave or "be left" According to him, in the past two years, more than 15 management cadres at or above the level of director of an enterprise have been replaced, which are also the "elderly" of older enterprises In fact, in terms of the development process of many local enterprises, some of the top executives of many enterprises join the company in the period of entrepreneurship, some of them join the company even when they are less than 20 years old, and even some of the relationship arrangements such as the relatives of the owners of enterprises are available, which is also a common phenomenon in China "These people grew up with the business The rapid development of the pharmaceutical industry in the past 20 years has made it easy for them to get the first pot of gold in their lives and go all the way to management positions, but in fact, they do not have professional knowledge and management system " The person said In his view, in the past "gold everywhere" era, people of any background can gain a lot if they are willing to work hard Some products, such as some commonly recognized auxiliary drugs, although the products do not have professional clinical advantages, but some people can also obtain a lot of capital in life by relying on relationship precipitation, public relations means and even tax avoidance ability Now they are 40-50 years old, or even older The inherent thinking formed over the years is difficult to change It is also difficult for enterprises to require some empiricists to make innovations At the same time, this part of people should also protect themselves and protect their vested interests as much as possible But for enterprises, if they do not change, they will not keep up with the development of the times "It's a question mark whether the Talents 10 years ago are still talents." Therefore, elimination and alternation become inevitable realistic needs Nowadays, a series of policy guidance, such as two vote system, generic drug consistency evaluation and traditional Chinese medicine injection evaluation, have an obvious impact on enterprises For example, after the two vote system, some executives who do not really grasp the channel resources will become empty shelves in some investment promotion enterprises Another example is the medical representative filing system, which requires few people to pass the threshold In particular, the thinking, ability and comprehensive quality of some early generations have been unable to cope with the new challenges proposed by the policy to some extent, and also difficult to adapt to the new requirements put forward by enterprises Under the current medical environment, with the overall adjustment of talent standards, enterprises are also required to build a new talent system The old generation of empiricists may be eliminated or realize real transformation, but only 10-20% of them can achieve real transformation In this situation, the decision-making level of the enterprise has to actively eliminate some people, and introduce talents with professional capabilities that match the development of the enterprise at this stage The former general manager of pharmaceutical enterprises pointed out that the current policy environment requires enterprises to take a professional path Whether it's M & A, R & D or marketing, this trend is becoming more and more prominent For example, the rapid development of Hengrui pharmaceutical in recent years is the best proof Therefore, in the future, the competitiveness of enterprises will depend more on the competition of professional talents, so the decision-makers of enterprises must also seize talents, and put the most competitive talents into the bag, which is also an important reason for the current part of people to leave and change jobs It has to be pointed out that in China, the pharmaceutical industry is not a complete market-oriented system The strategy and layout of enterprises should closely follow the policy changes, and the resulting talent adjustment is inevitable and sustainable 3 Change of senior executives in local enterprises: in the first half of this year, the change of senior executives is very frequent, including some senior professional managers at the level of vice president and president Only a part of the list that is well known in the industry and has public information is listed below: in July, Wu Yufeng, the employee representative supervisor of Yuheng pharmaceutical, resigned as the second employee representative supervisor of the company and still served as the director of human resources of the company In June, Liu ou, vice chairman of Bikang, resigned as vice chairman and director of the company, and resigned as a member of the strategy committee of the board of directors After resigning, he will no longer hold any post in the company In May, it was reported that Guan Shisong, vice president of Qianyuan pharmaceutical, resigned and will no longer hold any post in the company In May, sun liming, the board secretary and general manager of Asia Pacific Pharmaceutical Co., Ltd., resigned from other positions in the company In May, Jiang Ling, a director and executive deputy general manager of Haixiang pharmaceutical, resigned and no longer held any post in the company After that, Haixiang Pharmaceutical Co., Ltd appointed Li Hongming as the executive deputy general manager of the company At the end of April, Wang Minghui, the president of Yunnan Baiyao, was removed from the post of president and no longer retained the identity and relevant treatment of the leaders of the provincial state-owned enterprises In April, Zhao Gang, general manager of Qianhong Pharmaceutical Co., Ltd and director of the branch company resigned, but still served as chairman and director of the company In April, the former president of jiminxin, Shen Wenqiu, resigned Earlier in 2015, Xiong Guoqing, the former president of jiminxin, was removed from the post of president In April, Zhou Jiuping, chief operating officer of Watson biology, resigned as chief operating officer of the company In May, Yang Wenrui, general manager of Hejia pharmaceutical, resigned as the new general manager of the company At the same time, Gao Jiankui resigned from the position of deputy general manager and no longer held other positions in the company after resignation In April, Guo Leifeng, a director, deputy general manager and Secretary of the board of directors of Yuheng pharmaceutical, resigned and will serve as senior consultant of the company At the end of March, Zhongheng group appointed Yin Qi and Liao Zhi as vice general managers of the company Liu Weixiang and Xie Weixiang, former deputy general managers, left In February, Guo zhouke, chairman of North China pharmaceutical, resigned as a director and chairman of the company, as well as the chairman of the strategy committee of the board of directors of the company and the member of the nomination and remuneration assessment committee After resigning, he will no longer hold any post in the company According to February news, Miao Tianxiang, CEO of Haizheng Pfizer, a Sino foreign joint venture, has completed his one-year term of office as an agent He will be the CFO of Pfizer China again from March 1, and Li Yan will be the new CEO of Haizheng Pfizer Note: only a part of personnel change information with public information is listed above 4 personnel change of multinational pharmaceutical enterprises Similar to local pharmaceutical companies, in the first half of the year, multinational companies including Sanofi, AstraZeneca, Roche, Sanofi, Novartis, MSD and Takeda have made personnel adjustments in higher positions, with frequent news of resignations and new appointments The well-known personnel adjustment is listed as follows: in June, Lai Minglong, former vice president of Sanofi, joined AstraZeneca China management team and became Vice President of AstraZeneca China cardiovascular metabolism business department In May, Shan Guohong resigned as general manager of Pfizer innovation healthcare (PIH) in China Wu Kun was then appointed interim head of Pfizer innovation healthcare China Prior to that, Wu Kun was the general manager of the emergency business group of Pfizer core healthcare (Peh) in China After the appointment, Wu Kun will report directly to Nanette and become a member of the emerging market leadership team In May, Roche announced the appointment of Duanlian as the general manager of Roche Malaysia Before that, Duanlian was vice president of Shanghai Roche's anti infection and specialty drug business In June, Shanghai Roche pharmaceutical released an internal announcement, announcing that since August 1, 2017, Chen Shaofeng has been appointed Vice President of Shanghai Roche pharmaceutical's anti infection and specialty drug business department to take over Duanlian's work Before joining Roche, Chen Shaofeng took the post of head and vice president of general medicine business department in Merck China In May, it was reported that Lai Minglong, vice president of DBU, had decided to leave Sanofi From May 22, Patrick Nowlin, the current head of Sanofi's China business excellence department, took over In May, Mou Yanping was appointed as the general manager of the newly established cancer Business Department of MSD China Before that, Mou Yanping had worked for Johnson for many years At the same time, Tang Xingbin, former VP of North China, will go to the United States to serve as RML of MSD global vaccine in China Tang Xingbin has been working in China for more than 15 years and was promoted to be general manager of MSD Northeast China in 2015 In March, Cui Yi, head of China's original cancer business department in Takeda, was dismissed, and Deng Qingguang was later announced to take over Prior to that, Deng Qingguang served as the director of business excellence in Greater China In March, it was reported that Yin Xudong, chairman of Novartis China, would be promoted to the position of market director of Novartis Asia Pacific, Middle East and Africa, but still retain his position in China; Zhang Ying, current chief operating officer of Novartis China, would be promoted to the position of president of China Note: only a part of personnel change information with public information is listed above